Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun J. Lee, Ranjana J. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana A. Feldman, Stephen M. Ansell

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences